Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Invasive fungal infection (IFI) is a leading cause of infection-related mortality among patients with cancer and prolonged neutropenia and among allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Invasive candidiasis was the principal IFI in the period predating fluconazole prophylaxis, whereas today, invasive aspergillosis and other mold infections cause the majority of deaths from fungal infection in this patient population. The changing epidemiology of IFI, in addition to advances made in antifungal therapeutics and early diagnosis of IFI, warrant a reevaluation of earlier strategies aimed at prevention and early treatment of IFI that were developed several years ago. Here, we propose that persistent neutropenic fever is nonspecific for an IFI and should not be used as the sole criterion for empirical modification in the antifungal regimen in a patient receiving mold-active prophylaxis. We explore the potential benefits and gaps in knowledge associated with employing chest CT scans and laboratory markers as diagnostic adjuncts for IFI. Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, antifungal prophylaxis is now routinely used for extremely premature newborns in some neonatal units and for patients with certain types of hematologic malignancies, dramatically reducing rates of candidemia in these populations (15,16).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [15]
In the citing paper
“This might be due to increasing use of antifungal prophylactic regimens among patients with leukemia or lymphoma, patients who received bone marrow transplants, and chemotherapy recipients (15).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [15]
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Self-citationApoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2157::aid-cncr2820730821>3.0.co;2-1 · Cited by 2,135
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v · Cited by 1,360
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationGoodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · cited 1×
“gin with liposomal amphotericin B, the proportion of patients with a successful outcome in the different treatment arms was 26%–34% [29, 30].”
BackgroundSelf-citationDiagnosis of Invasive Aspergillosis Using a Galactomannan Assay: A Meta-Analysis
Pfeiffer, C. D., Fine, J. P., & Safdar, N. (2006) · Clinical Infectious Diseases · doi:10.1086/503427 · Cited by 962
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
Research works printed but not linked: 5
- AISNER, 1977, Annals of Internal Medicine, 86, 539, 10.1059/0003-4819-86-5-539 · doi:10.1059/0003-4819-86-5-539
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/171.6.1545 · doi:10.1093/jnlids/171.6.1545
- Marr, 2004, Current opinion in investigational drugs (London, England : 2000), 5, 202
- 2003, Blood, 2, 2
- 2003, Blood, 22, 22
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“The usefulness of other potentially active agents, such as itraconazole and AmB, in stem cell transplant recipients is limited by toxicity, drug-drug interactions, logistical issues, or bioavailability [295].”
BackgroundSelf-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationStevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citation
Metadata
- Authors
- Segal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Hôpitaux Universitaires de Strasbourg (FR)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Florida (US)
- Corresponding author
- Segal, B. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02-01
- Volume
- 44
- Issue
- 3
- Pages
- 402-409
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134986902
- Cited by
- 168
- References
- 77
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 6 · 2017: 3 · 2016: 5 · 2015: 6 · 2014: 11 · 2013: 10 · 2012: 8
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- invasive fungal infections, invasive candidiasis, invasive aspergillosis, mold infections, cancer patients, neutropenia, hematopoietic stem cell transplantation, graft-versus-host disease, antifungal prophylaxis, fluconazole, chest CT, laboratory biomarkers, early diagnosis, antifungal agents, clinical trial design
- MeSH terms
- Antifungal Agents, Evaluation Studies as Topic, Fever, Fungi, Galactose, Humans, Mannans, Mycoses, Neoplasms, Neutropenia, Tomography, X-Ray Computed, Yeasts, Biomarkers, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, beta-Glucans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. https://app.cochat.ai/papers/10.1086/510677
- The paper
- Segal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007). Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clinical Infectious Diseases. https://doi.org/10.1086/510677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.